Oncology

Urinary system
#Cancer treatment #China #Oncology #Phase II trial #Regulatory

Astellas’ urothelial cancer drug approved in China

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. Read More

#News #Regulatory

Antibodies attack cancer cell
#Antibodies #Cancer research #Cancer Research UK #Collaboration #Oncology #Partnership #UCB

CRUK and UCB advance oncology antibody candidates

Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical… Read More

#Cancer Research #News

Medical laboratory
#Antibody drug conjugate (ADC) #Bio-Thera Solutions #Cancer research #Oncology #Phase I trial #Solid tumours

Company launches ADC Phase I trial in solid tumours

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2.   Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with… Read More

#Cancer Research #News

Plague bacterium Yersinia pestis, scientifically accurate 3D illustration showing structure of the cell with DNA, plasmids and ribosomes
#Cancer research #CureLab Oncology #Gene therapy #Investment #Oncology #Plasmid DNA

Oncology company receives $3M from biotech investor

Dr John Ballantyne, co-founder of Aldevron, has invested $3 million in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr Ballantyne served there as chief scientific officer. Both CureLab Oncology and CureLab Veterinary are… Read More

#Business & Investment #News

#Cancer research #Cancer treatment #CAR-T #Cell therapy #Drug discovery #Epigenetics #Immunotherapy #Oncology

New episode of the DDW Highlights podcast available

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As well as providing extensive coverage of the … Read More

#News

#Cancer research #Cancer treatment #CAR-T #Cell therapy #Drug discovery #Epigenetics #Immunotherapy #Oncology

This week in drug discovery (27 February – 3 March)

News round-up for 27 February – 3 March by DDW Digital Content Editor Diana Spencer.  As well as providing extensive coverage of the SLAS2023 meeting in San Diego and Rare Disease Day, DDW has also reported on a… Read More

#News

Pancreatic cancer cells
#Cancer research #Nanomedicine / nanotechnology #Oncology #Pancreatic cancer #RNA #SiSaf

Partnership will develop targeted miRNAs to treat pancreatic cancer

SiSaf is to collaborate with the University of Leipzig, Germany, to develop targeted micro interfering RNAs (miRNA) for the treatment of cancer, with an initial focus on pancreatic cancer.   The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier silicon-stabilised hybrid lipid nanoparticles (sshLNPs) and… Read More

#Cancer Research #News

CAR-T cell attacking cancer
#Cancer immunotherapy #Cancer research #CAR-T #Cell therapy #Immunotherapy #Karolinska Institutet #Oncology

CAR-T cell therapy holds promise for ovarian cancer

CAR-T cell therapy is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.   The study authors, who work at Karolinska Institutet, hope that the discovery will pave the way for a clinical trial… Read More

#Cancer Research #News #Trending News

Laboratory research
#Cancer research #Collaboration #Drug discovery #Oncology #Partnership #Target identification #Target validation

Partners from UK and Singapore agree cancer drug discovery deal

Cancer Research Horizons and Singapore’s Experimental Drug Development Centre (EDDC) have announced a five-year strategic partnership to accelerate the translation of cancer research into improved treatments for cancer patients.   The international alliance will focus on leveraging the complementary capabilities, platforms and technologies from both partners, to accelerate… Read More

#Cancer Research #News

#Avacta #Cancer research #CAR-T #Cell therapy #Immunotherapy #Oncology #Precision medicine #T cell activation #Therapeutic targets

Precision cancer therapies: Where are we?

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview… Read More

#Cancer Research #Exclusive Content

Research in genetics laboratory
#Cancer research #Epigenetics #Gene expression #Genetics / genomics #Oncology #The Institute of Cancer Research

Epigenetics discovery could lead to new class of cancer drugs

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs.  Epigenetics is still largely unexplored and referred to as the ‘dark matter’… Read More

#Cancer Research #Editor's Choice #News

Male patient with doctor
#Cancer research #CHMP #European Medicines Agency #Gene mutation #Oncology #Phase III trial #Prostate cancer

Prostate cancer combination therapy reduces risk of death

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.  Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by… Read More

#News #Regulatory

Prostate cancer cells
#Cancer research #Genetics / genomics #Janssen #Oncology #Phase III trial #Prostate cancer

PARP inhibitor slows progression in HRR-positive prostate cancer

Janssen has revealed updated results from the Phase III MAGNITUDE study, which show that a combination therapy including niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, slowed prostate cancer progression.  The drug was investigated in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate… Read More

#Cancer Research #News

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News

Clinical trials
#Breast cancer #Cancer research #Clinical research #Clinical trials #Covid-19 #Oncology

What are the top disease areas for clinical drug trials?

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. Here, we take a look at the top four disease areas and some of the key developments in 2022.  1. Breast cancer In… Read More

#Exclusive Content

Macrophage
#Cancer research #Immunology #Macomics #Mass spectrometry / NMR #Oncology #Transcriptomics #Tumour biology #Tumour microenvironment (TME)

Scottish company will target macrophages to treat cancer

Newly published discoveries have revealed possibilities for the treatment of cancer by targeting tumour-associated macrophages (TAMs) in the tumour microenvironment (TME).  The founding scientists behind Edinburgh-based Macomics, Dr Luca Cassetta and Professor Jeff Pollard, detail the seminal discoveries in macrophage biology over the past 50 years in… Read More

#Cancer Research #News